atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai has administered the first dosage of their VLS-01 synthetic DMT drug in their Phase 1 single-ascending dose (SAD) trial, with topline results expected to come back sometime during the first half of 2023. VLS-01 is a synthetic form of N, N-dimethyltryptamine (DMT) being developed to treat depression that doesn’t respond to other treatments. atai’s digital therapeutic will provide support to patients before they take the VLS-01 dose. This includes helping them understand how the environment and mindset can affect their experience. More than 100 million people worldwide suffer from treatment-resistant depression. atai Life Sciences N.V. (Nasdaq: ATAI) recently announced The post atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial appeared first on Psychedelic Chronicle.